A 24-WEEK RANDOMIZED, DOUBLE-BLIND, MULTI-CENTER, ACTIVE-CONTROLLED (PIOGLITA

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。需要新的、更好的抗糖尿病药物。这项多国家、多中心研究的目的是比较新的PPAR伽玛激动剂他格列塔与标准疗法的有效性、安全性和耐受性。初步数据表明，他格列塔至少与标准疗法一样有效，并可能对2型糖尿病受试者的降脂有额外的影响。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. There is a need for new and better anti-diabetic drugs. The aim of this multi national, multicenter study is to compare the efficacy, safety and tolerability of the new ppar gamma activator tesaglitazar with standard therapy. Preliminary data suggest that tesaglitazar is at least as effective as standard therapy and may have additional effects to lower lipids in type 2 diabetic subjects.